Related Experiment Video

Updated: Jul 14, 2026

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis

A I Kim1, A Dorn, R Bouajram

  • 1Division of Infectious Diseases, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.

HIV Medicine
|June 15, 2007
PubMed

Insights

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection accelerates disease. Peginterferon plus ribavirin significantly improves sustained virological response in coinfected patients without increasing adverse events.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) coinfection with human immunodeficiency virus (HIV) accelerates disease progression.
  • The increasing lifespan of coinfected patients necessitates understanding HCV management strategies.
  • Previous studies suggest varying efficacy of interferon-based therapies for HCV in coinfected individuals.

Purpose of the Study:

  • To evaluate the efficacy and safety of peginterferon plus ribavirin compared to interferon-based regimens for chronic HCV/HIV coinfection.
  • To analyze sustained virological response (SVR) rates across different HCV genotypes.
  • To assess safety concerns, including severe adverse effects and treatment withdrawal rates.

Main Methods:

  • Systematic review and meta-analysis of prospective randomized controlled trials (RCTs).
  • Searched MEDLINE and Cochrane databases (1966-2005) and national meeting abstracts (2001-2005).
  • Included trials comparing peginterferon plus ribavirin against peginterferon or interferon plus ribavirin.

Main Results:

  • Peginterferon plus ribavirin demonstrated significantly higher SVR rates compared to interferon plus ribavirin (OR 3.00).
  • This benefit was observed across HCV genotypes 1/4 (OR 4.40) and 2/3 (OR 2.56).
  • Peginterferon plus ribavirin also showed higher SVR than peginterferon monotherapy (OR 2.60), with similar rates of severe adverse effects and withdrawal.

Conclusions:

  • Peginterferon plus ribavirin is a more effective treatment for achieving SVR in patients with chronic HCV/HIV coinfection.
  • This combination therapy offers improved outcomes without a significant increase in serious adverse events or treatment discontinuation.
  • These findings support the use of peginterferon plus ribavirin for managing HCV in coinfected populations.
Abstract

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...